Clinical study on treatment of early diabetic nephropathy by extract of gingko biloba / 中国综合临床

ABSTRACT

objective To investigate the protective effect and possible mechanisms of extract of Gingko biloba(EGB)on early diabetic nephropathy(DN).Methods Fifty-one patients with early DN were randomly divided into control group(n=25)treated by irbesartan alone and treated group(n=26)treated by EGB combined with irbesartan.Serum high sensitive C-reactive protein(hs-CRP)and monocyte chemoattractant protein-1(MCP-1)were determined with ELISA before and after treatment,and urinary albumin excretion rate(UAER),fasting blood glucose (FBG),serum creatinine(SCr),blood urea nitrogen(BUN)and lipid profiles were examined as well.Results Compared with pretreatment,at the end of 6 months'treatment,the values of hs-CRP decreased from(194.37±34.02)and(191.51±27.15)mg/L to(164.13±32.86)and(134.65±20.47)mg/L in control group and treatment group,respectively.MCP-1 was downregulated from(304.23±38.56)and(299.66±44.07)ng/L to (235.43±28.66)and(165.53±21.96)ng/L in control group and treated group(all P＜0.05).After treatment,the decrement of hs-CRP and MCP-1 level in the treated group was more significant than that in control group(P＜0.05).Conclusion EGB could retard the development of early DN,through down-regulating the expresssion of seram MCP-1,decreasing serum hs-CRP concentration and inhibiting inflammatory reaction.